Attovia Therapeutics, Inc. (NasdaqGM: ATTO)
Health Care · Biotechnology · US
$15.13
-4.30% today · -30.9% 1Y
Attovia Therapeutics, Inc. (NasdaqGM: ATTO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $690.70M and employs 44 people.
Over the last twelve months the share price has lost 30.9%, trading between 12.94 and 28.00.
Tweenvest scores Attovia Therapeutics, Inc. across four factors: quality 45/100, value 76/100. Its strongest factor is value.
ATTO price history
Key figures
- Market cap
- $690.70M
- Revenue (TTM)
- $1.44M
- P/E
- -9.81
- EPS
- -16.97
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $28.00
- 52-week low
- $12.94
- Avg volume (3M)
- —
- Shares outstanding
- 45.65M
- Employees
- 44
- Next earnings
- —
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
- ISIN
- US04987L1026
- Founded
- 2022
- Listed since
- Aug 5, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Solid Biosciences Inc.NasdaqGS: SLDB | $708.73M | $6.35 | +1.93% |
| CARsgen Therapeutics Holdings LimitedSEHK: 2171 | $699.39M | HK$9.76 | -3.37% |
| Nuvectis Pharma, Inc.NasdaqCM: NVCT | $696.03M | $20.24 | +0.05% |
| Achieve Life Sciences, Inc.NasdaqCM: QUIT | $695.42M | $6.32 | +0.48% |
| 4D Molecular Therapeutics, Inc.NasdaqGS: FDMT | $689.52M | $12.23 | +0.95% |
| Prime Medicine, Inc.NasdaqGM: PRME | $681.67M | $3.82 | -0.13% |
| Kura Oncology, Inc.NasdaqGS: KURA | $674.39M | $7.34 | -2.00% |
| ArriVent BioPharma, Inc.NasdaqGM: AVBP | $672.92M | $13.01 | -0.46% |